Muscle Spasticity – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Muscle Spasticity – Drugs In Development, 2024 report and make more profitable business decisions.
Muscle spasticity is a condition that causes muscles to contract, stiffen, or spasm involuntarily, affecting movement, speech, and gait. It is caused by damage or disruption to the nerve pathways that control muscle movement, usually due to brain or spinal cord injury, cerebral palsy, multiple sclerosis, or other diseases. Spasticity can range from mild to severe and can cause pain, deformity, fatigue, and difficulty performing daily tasks. Spasticity can be treated with physical therapy, medication, surgery, or other methods depending on the cause and severity of the condition.
The Muscle Spasticity drugs in development market research report provide comprehensive information on the therapeutics under development for Muscle Spasticity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscle Spasticity and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Muscle Spasticity | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 32 molecules, with 31 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Muscle Spasticity therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Muscle Spasticity pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Muscle Spasticity treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAix-Marseille University
CKD Bio Corp
CytoDel Inc
Delpor Inc
Echo Pharmaceuticals BV
Engrail Therapeutics Inc
Ethicann Pharmaceuticals Inc
Genochem SAS
Huons Co Ltd
Huons Global Co Ltd
Incannex Healthcare Ltd
Ipsen SA
Malachite Innovations Inc
Merz Pharma GmbH & Co KgaA
Microgen
Motric Bio Inc
Osmotica Pharmaceutical Corp
Phase V Pharmaceuticals Inc
Revance Therapeutics Inc
Sania Therapeutics Inc
SANOCHEMIA Pharmazeutika GmbH
Saol Therapeutics Inc
Sentynl Therapeutics Inc
Shionogi & Co Ltd
Sun Pharma Advanced Research Company Ltd
Supernus Pharmaceuticals Inc
Tris Pharma Inc
Viatris Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Muscle Spasticity reports